Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valves, Neurovascular, Diabetes Highlight Medtronic’s Fiscal 2016 Performance

This article was originally published in Clinica

Executive Summary

Medtronic is declaring its first full year since merging with Covidien a success, with continued mid-single digit revenue growth and $355m in integration synergies, the company announced May 31.

Advertisement

Related Content

HRS 2017: EBR's Leadless CRT Feasibility; Watchman Registry Data; A Novel AF Ablation Catheter From BW; And More Medtronic CRT Data
Medtronic Misses Mid-Year Mark With 'Disappointing' 3% Growth
OUS Approvals Analysis: Summer Brings Slowdown In CE Marks

Topics

Advertisement
UsernamePublicRestriction

Register

MT103468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel